Title: Safety and Efficacy Analysis of Chemoradiotherapy/Radiotherapy Combined with
Nimotuzumab for Treating Advanced Unresectable Oesophageal Squamous Cell Carcinoma in
Elderly Patients: A Retrospective Analysis
Version: 0 Date: 13 Jun 2022
Reviewer:  Madhup Rastogi
Reviewer's report:
Esophageal cancers are a challenge for any oncologist and it becomes more difficult when
patient is of geriatric age group. Your option of adding Nimotuzumab along with chemotherapy
and also as single modality with radiotherapy seems to be pretty beneficial for such patients.
Nimotuzumab has already shown benefit to Head and neck cancer patients as concurrent
chemoradiotherapy. Well conducted study. I will suggest prospective evaluation of adding
nimotuzumab along with concurrent chemotherapy in all the esophageal cancer patients
undergoing upfront radiotherapy to evaluate the outcome and comparison with the available
modality of treatment in the form of Concurrent Chemoradiotherapy.
Title: Safety and Efficacy Analysis of Chemoradiotherapy/Radiotherapy Combined with
Nimotuzumab for Treating Advanced Unresectable Oesophageal Squamous Cell Carcinoma in
Elderly Patients: A Retrospective Analysis
Version: 0 Date: 13 Jun 2022
Reviewer:  Madhup Rastogi
Reviewer's report:
Esophageal cancers are a challenge for any oncologist and it becomes more difficult when
patient is of geriatric age group. Your option of adding Nimotuzumab along with chemotherapy
and also as single modality with radiotherapy seems to be pretty beneficial for such patients.
Nimotuzumab has already shown benefit to Head and neck cancer patients as concurrent
chemoradiotherapy. Well conducted study. I will suggest prospective evaluation of adding
nimotuzumab along with concurrent chemotherapy in all the esophageal cancer patients
undergoing upfront radiotherapy to evaluate the outcome and comparison with the available
modality of treatment in the form of Concurrent Chemoradiotherapy.
Please review this paper.
user
Title: Safety and Efficacy Analysis of Chemoradiotherapy/Radiotherapy Combined with
Nimotuzumab for Treating Advanced Unresectable Oesophageal Squamous Cell Carcinoma in
Elderly Patients: A Retrospective Analysis
Version: 0 Date: 13 Jun 2022
Reviewer:  Madhup Rastogi
Reviewer's report:
Esophageal cancers are a challenge for any oncologist and it becomes more difficult when
patient is of geriatric age group. Your option of adding Nimotuzumab along with chemotherapy
and also as single modality with radiotherapy seems to be pretty beneficial for such patients.
Nimotuzumab has already shown benefit to Head and neck cancer patients as concurrent
chemoradiotherapy. Well conducted study. I will suggest prospective evaluation of adding
nimotuzumab along with concurrent chemotherapy in all the esophageal cancer patients
undergoing upfront radiotherapy to evaluate the outcome and comparison with the available
modality of treatment in the form of Concurrent Chemoradiotherapy.
assistant